BioNTech SE American Depositary Share
BioNTech SE American Depositary S.../ US09075V1026 /
BNTX
05/06/2024 21:59:59
|
Chg.
+2.97
|
Volume |
Bid- |
Demandez à- |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
102.55USD
|
+2.98%
|
41,715 Chiffrre d'affaires: 4.19 Mio. |
-Bid taille: - |
-Ask la taille: - |
-USD |
- |
- |
Description de l'entreprise
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Conseil d'administration & Conseil de surveillance
PDG |
Ugur Sahin |
Conseil d'administration |
Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting |
Conseil de surveillance |
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider |
Données de l'entreprise
Nom: |
BioNTech SE |
Adresse: |
An der Goldgrube 12,DE-55131 Mainz |
Téléphone: |
+49-6131-9084-0 |
Fax: |
+49-6131-9084-390 |
Courriel: |
info@biontech.de
|
Internet: |
https://biontech.de/de |
Industrie: |
Biotechnology |
Secteur: |
Biotechnology |
Sous-secteur: |
Biotechnology |
Fin de l'exercice financier: |
31/12 |
Flotte libre: |
- |
IPO date: |
- |
Relations avec les investisseurs
Nom: |
Dr. Sylke Maas |
Téléphone IR: |
- |
IR-Fax: |
- |
E-mail IR: |
Investors@biontech.de
|
Calendrier de l'entreprise
CW 32 | 05/08/2024
Interim Report 2nd Quarter/6 Months
|
CW 45 | 04/11/2024
Interim Report 3rd Quarter/9 Months
|
Principaux actionnaires
AT Impf GmbH |
|
50.33% |
Freefloat |
|
19.70% |
Medine GmbH |
|
18.38% |
MIG Verwaltungs AG |
|
5.98% |
FMR LLC |
|
5.61% |